Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hippo Signaling Pathway Regulates Cancer Cell-Intrinsic MHC-II Expression.
Zeng Z, Gu SS, Ouardaoui N, Tymm C, Yang L, Wong CJ, Li D, Zhang W, Wang X, Weirather JL, Rodig SJ, Hodi FS, Brown M, Liu XS. Zeng Z, et al. Among authors: rodig sj. Cancer Immunol Res. 2022 Dec 2;10(12):1559-1569. doi: 10.1158/2326-6066.CIR-22-0227. Cancer Immunol Res. 2022. PMID: 36219700
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA. Sasaki T, et al. Among authors: rodig sj. Cancer Res. 2011 Sep 15;71(18):6051-60. doi: 10.1158/0008-5472.CAN-11-1340. Epub 2011 Jul 26. Cancer Res. 2011. PMID: 21791641 Free PMC article.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D. Hodi FS, et al. Cancer Immunol Res. 2014 Jul;2(7):632-42. doi: 10.1158/2326-6066.CIR-14-0053. Epub 2014 Apr 21. Cancer Immunol Res. 2014. PMID: 24838938 Free PMC article. Clinical Trial.
Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.
Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, Helmkamp J, Sholl L, Carter SL, Oxnard G, Janne P, Getz G, Lindeman N, Hammerman PS, Garraway LA, Hodi FS, Rodig SJ, Dranoff G, Wong KK, Barbie DA. Van Allen EM, et al. Among authors: rodig sj. Cancer Immunol Res. 2015 Aug;3(8):855-63. doi: 10.1158/2326-6066.CIR-15-0024. Epub 2015 May 26. Cancer Immunol Res. 2015. PMID: 26014096 Free PMC article.
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma.
Derks S, Nason KS, Liao X, Stachler MD, Liu KX, Liu JB, Sicinska E, Goldberg MS, Freeman GJ, Rodig SJ, Davison JM, Bass AJ. Derks S, et al. Among authors: rodig sj. Cancer Immunol Res. 2015 Oct;3(10):1123-1129. doi: 10.1158/2326-6066.CIR-15-0046. Epub 2015 Jun 16. Cancer Immunol Res. 2015. PMID: 26081225 Free PMC article.
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.
Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ. Reardon DA, et al. Among authors: rodig sj. Cancer Immunol Res. 2016 Feb;4(2):124-35. doi: 10.1158/2326-6066.CIR-15-0151. Epub 2015 Nov 6. Cancer Immunol Res. 2016. PMID: 26546453
346 results